<DOC>
	<DOC>NCT02654639</DOC>
	<brief_summary>Phase II study of TAS-102 plus bevacizumab switch maintenance therapy in patients with mCRC</brief_summary>
	<brief_title>Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer</brief_title>
	<detailed_description>Study Drug: TAS-102 (trifluridine and tipiracil hydrocholoride) and bevacizumab Dosing Details: Starting dose of TAS-102 is 35 mg/m2 administered orally twice daily, after meals, for 5 days a week with 2 days rest for 14 days, followed by 14 days rest (1 treatment cycle). Bevacizumab 5 mg/kg intravenously every 14 days. The treatment cycle repeats every 28 days. Patients may take TAS-102 plus bevacizumab until they exhibit progression of disease, withdraw consent, or experience unacceptable toxicity.This is a single arm study. All patients receive the same study treatment.</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Trifluridine</mesh_term>
	<criteria>Inclusion criteria: Written informed consent Histologically proven, unresectable, evaluable metastatic colorectal cancer 16 to 20 weeks of firstline therapy with oxaliplatin, and/or irinotecanbased flourorpyrimidinecontaining chemotherapy plus Bevacizumab Patients must have stable disease (or better) during the initial induction chemotherapy with firstline chemotherapy. No progressive disease at the time of initiation of maintenance therapy Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1 Adequate organ and marrow function Women of childbearing potential and men must agree to avoid pregnancy Patient must start maintenance therapy at least 14 days after the last administered induction chemotherapy but no later than 30 days. Exclusion Criteria Patients whose tumors have progressed on firstline treatment Patients with active concurrent malignancy, other than superficial, noninvasive squamous cell carcinoma of the skin or uterine cervix, within the past three years. Women who are pregnant or lactating Unstable heart disease Uncontrolled active infection requiring antibiotics within one week prior to first dose. Patients with active CNS malignancy. Persistent protein in the urine Patients with bowel obstruction or uncontrolled vomiting. Patients with serious psychiatric or medical conditions that could interfere with treatment.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Metastatic Colorectal Cancer</keyword>
	<keyword>Advanced Colorectal Cancer</keyword>
</DOC>